Medicinal Chemistry Group
History of the group
The University of Liverpool Medicinal Chemistry group along with collaborators from the Liverpool School of Tropical medicine have been involved in discovery and development of compounds for treating diseases for over 25 years delivering 3 treatments into man (LapDap, LapDap+ and Isoquine), 3 clinical candidates and 5 pre-clinical candidates in malaria, tuberculosis and helminths. During this period we have successfully worked with pharma, including GSK, Astra Zeneca, Pfizer, Eisai and Abbvie. We work in number of drug development projects that are currently at the lead optimisation phase (funded by the Wellcome Trust, Leverhulme Trust, EU, MMV and Gates Foundation). The Liverpool team has also been involved in large drug-development consortia such as the EU funded Antimal, Artemip and CRIMALDI and the Gates funded MiP and AWOL drug development programmes.
We have proven experience in design and synthesis of novel compounds for the treatment of diseases. Molecular design and optimisation is integrated with computational chemistry, biological assay data and compound physicochemical properties.
We are situated within the Department of Chemistry. In the 2014 Research Excellence Framework (REF) the Department of Chemistry was ranked 2nd in the UK overall. We are well equipped with modern synthetic laboratories including microwave synthetic capabilities, computational hardware and software and departmental analytical services including NMR, mass-spectrometry, elemental analysis and HPLC.
Funding and collaboration
ds are extremely fortunate, and grateful, that this research is funded by research councils, charities and industry. This funds enable extremely productive collaborations with academia and industry.